Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Govt OKs Action Plan on Drug Resistance
Cabinet ministers officially adopted an action plan on antimicrobial resistance on April 5, which calls for reducing the volume-based use of antimicrobials by 33% by 2020 from the 2013 level. After the day’s Cabinet meeting, Health Minister Yasuhisa Shiozaki told…
To read the full story
Related Article
- Govt Panel to Draw Up New AMR Action Plan for 2021 and Beyond
November 29, 2019
- Less than 40% of Public Aware that Antibacterials Are Ineffective Against Common Cold: Govt Survey
October 15, 2019
- MHLW Begins Drafting Manual on Proper Use of Antibiotics for Clinicians
December 21, 2016
- MRSA Infections Add 190 Billion Yen Annually to Medical Expenditure at DPC Hospitals: MHLW Study Group
July 25, 2016
- Govt Aims to Reduce Use of Antimicrobials by 33% by FY2020 as Part of Efforts to Fight Resistance
April 5, 2016
- Japan to Draw Up Action Plan on Drug Resistance: Health Minister
December 16, 2015
REGULATORY
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
- Oncolys’ Telomelysin Wins Backing from Japan Panel
May 22, 2026
- MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
May 21, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…